Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 + Durvalumab + Tremelimumab in Advanced Hepatocellular Carcinoma
NCT06710223Phase 1Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nelitolimod in hepatocellular carcinoma (HCC), sponsored by University of California, San Diego. Primary endpoint: Adverse Events at 6 months. Started Jan 2025; status: active, not recruiting.
02
Drugs
nelitolimod
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06710223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710223.